Article info
PDFTherapeutics
Randomised controlled trial
In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding
- Correspondence to: Renato D Lopes
Cardiology, Duke University Medical Center, Duke Clinical Research Institute, Box 3850, 2400 Pratt Street, Room 0311, Durham, NC 27705, USA; renato.lopes{at}duke.edu
Citation
In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding
Publication history
- First published July 29, 2011.
Online issue publication
October 25, 2017
Article Versions
- Previous version (25 October 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions